Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 5/20 | 0.51 |
| ▸ | CHRNG | P07510 | 5/20 | 0.51 |
| ▸ | CHRNB1 | P11230 | 5/20 | 0.51 |
| ▸ | CHRND | Q07001 | 5/20 | 0.51 |
| ▸ | GRIA1 | P42261 | 6/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24991172 | 0.85 | PSMB8 (0.47) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL23750093 | 0.80 | CHRNA1 (0.42) | CHRNA1CHRNGCHRNB1CHRNDGRIA1 | |
| SCHEMBL16485165 | 0.74 | CHRNA1 (0.54) | CHRNA1CHRNGCHRNB1CHRNDGRIA1 | |
| SCHEMBL23750092 | 0.74 | CHRNA1 (0.47) | CHRNA1CHRNGCHRNB1CHRNDGRIA1 | |
| SCHEMBL12510278 | 0.74 | NPY4R (0.49) | — | |
| SCHEMBL16485174 | 0.72 | CHRNB2 (0.52) | CHRNA1CHRNGCHRNB1CHRNDGRIA1 | |
| SCHEMBL24991021 | 0.71 | IL23R (0.57) | — | |
| SCHEMBL30179134 | 0.70 | GNPAT (0.52) | CHRNA1CHRNGCHRNB1CHRNDOPRD1 | |
| SCHEMBL30179445 | 0.69 | TFPI (0.48) | — | |
| SCHEMBL30179352 | 0.69 | TFPI (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | PALATIN TECHNOLOGIES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | MC1R, MC3R, MC5R | CHRNA1 673/4885CHRNG 500/4885CHRNB1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.